SPARC gene expression is increased in diabetes-related mesenteric vascular hypertrophy

Microvascular Research

Volumn 59, Issue 1, 2000, Pages 61-71

  Jandeleit Dahm, K ^b   Rumble, J ^a   Cox, A J ^a   Kelly, D J ^a   Dziadek, M ^a   Cooper, M E ^a   Gilbert, R E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Diabetes mellitus; Mesenteric vessels; mRNA; Osteonectin; Remodeling; SPARC; Vascular hypertrophy

Indexed keywords

AMINOGUANIDINE; OSTEONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HYPERTROPHY; MESENTERY BLOOD VESSEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0033974212     PISSN: 00262862     EISSN: None     Source Type: Journal    
DOI: 10.1006/mvre.1999.2189     Document Type: Article

References (30)

1. Allen T. J., Cooper M. E., O'Brien R. C., Bach L. A., Jackson B., Jerums G. Glomerular filtration rate in the streptozocin diabetic rat: The role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes. 38:1990;1182-1190.
2. Brownlee M., Cerami A., Vlassara H., Greene D. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications: The pathogenesis and prevention of diabetic neuropathy and nephropathy. N. Engl. J. Med. 318:1988;1315-1321.
3. Bunag R. D. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J. Appl. Physiol. 34:1973;279-282.
4. Cao Z. M., Hulthen U. L., Allen T. J., Cooper M. E. Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. J. Hypertens. 16:1998;793-799.
5. Chiquet-Ehrismann R. Anti-adhesive molecules of the extracellular matrix. Curr. Opin. Cell. Biol. 3:1991;800-804.
6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
7. Cooper M. E., Rumble J., Komers R., Du H. C., Jandeleit K., Chou S. T. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes. 43:1994;1221-1228.
8. Dodge A. B., D'Amore P. A. Cell-cell interactions in diabetic angiopathy. Diabetes Care. 15:1992;1168-1180.
9. Duncan M. K., Shimamura T., Chada K. Expression of the helix-loop-helix protein, Id, during branching morphogenesis in the kidney. Kidney Int. 46:1994;324-332.
10. Dziadek M., Paulsson M., Aumailley M., Timpl R. Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumour. Eur. J. Biochem. 161:1986;455-464.
11. Funk S. E., Sage E. H. The Ca2+-binding protein that modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA. 88:1991;2648-2652.
12. Gilbert R. E., McNally P. G., Cox A., Dziadek M., Rumble J., Cooper M. E., Jerums G. SPARC gene expression is reduced in early diabetes-related kidney growth. Kidney Int. 48:1995;1216-1225.
13. Griffin S. A., Brown W. C., MacPherson F., McGrath J. C., Wilson V. G., Korsgaard N., Mulvany M. J., Lever A. F. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 17:1991;626-635.
14. Heagerty A. M., Aalkjaer C., Bund S. J., Korsgaard N., Mulvany M. J. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension. 21:1993;391-397.
15. Lane T. F., Iruela-Arispe M. L., Sage E. H. Regulation of gene expression by SPARC during angiogenesis in vitro. J. Biol. Chem. 267:1992;16736-16745.
16. Lane T. F., Sage E. H. The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8:1994;163-173.
17. Mayer U., Aumailley M., Mann K., Timpl R., Engel J. Calcium-dependent binding of basement membrane protein BM-40 (osteonectin, SPARC) to basement membrane collagen type IV. Eur. J. Biochem. 198:1991;141-150.
18. Monnier V. M., Sell D. R., Nagaraj R. H., Miyata S., Grandhee S., Odetti P., Ibrahim S. A. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes. 2:1992;36-41.
19. Pichler R. H., Hugo C., Shankland S. J., Reed M. J., Bassuk J. A., Andoh T. F., Lombardi D. M., Schwartz S. M., Bennett W. B., Alpers C. E., Sage E. H., Johnson R. J., Couser W. G. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int. 50:1996;1978-1989.
20. Porter P. L., Sage E. H., Lane T. F., Funk S. E., Gown A. M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem. 43:1995;791-800.
21. Raines E. W., Lane T. F., Iruela-Arispe M. L., Ross R., Sage E. H. The extracellular glycoprotein SPARC interacts with platelet derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc. Natl. Acad. Sci. USA. 89:1992;1281-1285.
22. Rumble J. R., Cooper M. E., Soulis T., Cox A., Wu L., Youssef S., Jasik M., Jerums G., Gilbert R. E. Vascular hypertrophy in experimental diabetes: Role of advanced glycation end products. J. Clin. Invest. 99:1997;1016-1027.
23. Sage E. H., Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin and thrombospondin. J. Biol. Chem. 266:1991;14831-14834.
24. Schmidt F. H. Enzymatic determination of glucose and fructose simultaneously. Klin. Woch. 39:1961;1244-1247.
25. Simonsen U., Ehrnrooth E., Gerdes L. U., Faergemann O., Buch J., Andreasen F., Mulvany M. J. Functional properties in vitro of systemic small arteries from rabbits fed a cholesterol-rich diet for 12 weeks. Clin. Sci. 80:1991;119-129.
26. Soulis T., Cooper M. E., Vranes D., Bucala R., Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int. 50:1996;627-634.
27. Tremble P. M., Lane T. F., Sage E. H., Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodelling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell. Biol. 121:1993;1433-1444.
28. Vranes D., Cooper M. E., Dilley R. J. Cellular mechanisms of diabetic vascular hypertrophy. Microvasc. Res. 57:1999;8-18.
29. Wrana J. L., Overall C. M., Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur. J. Biochem. 197:1991;519-528.
30. Wu L., Cox A., Roe C., Dziadek M., Cooper M. E., Gilbert R. E. Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system. J. Am. Soc. Nephrol. 8:1997;1374-1382.